Gene therapy for inherited blindness sets precedent: $850,000 price tag
By Carolyn Y. Johnson,
Washington Post
| 01. 03. 2018
A landmark gene therapy to treat a rare, inherited form of blindness will cost $850,000 — a price tag so daunting that its maker will offer health insurers partial rebates if the drug doesn't work and is seeking to pilot an installment payment option.
The drug, called Luxturna, is the realization of a long-sought scientific dream: The one-time treatment corrects a faulty gene to improve vision, allowing patients to see the stars or their parents' faces. Only 1,000 to 2,000 people in the United States are thought to have deteriorating vision caused by this errant gene, called RPE65, but Luxturna is widely expected to be the first in a wave of cutting-edge treatments that are targeted at fixing the causes of a wide range of genetic diseases — while also raising difficult questions about how to pay for them.
The idea that drugs can be made to correct the defective genes that lie at the root of inherited diseases has long tantalized medicine. Nearly three decades ago, gene therapy was first tested in a patient in the U.S., but after a teenager named Jesse Gelsinger died in a clinical trial in 1999, the field screeched to a...
Related Articles
By Natalie Ram, Anya E. R. Prince, Jessica L. Roberts, Dov Fox, and Kayte Spector-Bagdady, Science | 09.11.2025
After declaring bankruptcy in March 2025, direct-to-consumer (DTC) genetic testing company 23andMe sold the data of more than 15 million people around the world to TTAM Research Institute, a nonprofit organization created by 23andMe’s founder and long-time CEO. 23andMe’s customers...
By Gina Kolata, The New York Times | 09.22.2025
On May 26, Tracy Atteberry checked in to the hospital at the National Institutes of Health in Bethesda, Md. The 57-year-old has an ultrarare inherited disease that hobbles his immune system so that the most innocuous of germs could kill...
By Jackie Davalos, Bloomberg | 09.15.2025
Kindbody, one of the largest fertility companies in the US, sought to disrupt egg freezing and IVF by combining spa vibes with Silicon Valley efficiency. The startup raised millions, opened dozens of clinics, and became a billion-dollar unicorn. But its...
By Vuyile Madwantsi, Independent Online | 08.22.2025
Imagine this: a future where parents could choose their baby’s eye colour, height or even intelligence.
Sounds like science fiction, right? But it’s closer than you think.
Let’s start with a simple, human truth: most of us want healthy children...